A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
The purpose of this study is to determine the maximum-tolerated dose (MTD) of dinaciclib
therapy in combination with rituximab in chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL).
Clinical Trial Conditions: Chronic Lymphocytic Leukemia, Small Lymphoctyic Lymphoma
Treatments in this Clinical Trial : Dinaciclib, Rituximab
Clinical Trial Phase: Phase 1
Eligible Clinical Trial Participant Age : Between 18 years to 100 years
Can Healthy Volunteers Participate: No
Clinical Trial Lead Sponsor: Merck
Detailed Clinical Trial Description: The purpose of this study is to determine the maximum-tolerated dose (MTD) of dinaciclib
therapy in combination with rituximab in chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL).
The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01650727
